26-12-2011 21:20 Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism.

Read the original post:
China medical tourism--Brain Injury--stem cells therapy - Video

(HealthDay News) -- Many older Americans get screened for colon, breast, prostate and cervical cancer even though guidelines recommend against routinely screening the elderly, a new study finds.

As the population of the United States continues to age, balancing good health care with costs will be a continuing battle, experts say. "In an era of escalating health care utilization and expenditures in the United States, identifying areas for cost containment while concurrently improving quality of care in our health care system is increasingly paramount," said lead researcher Keith Bellizzi, an assistant professor of human development and family studies at the University of Connecticut in Storrs.

"Perhaps this area of health care warrants further attention," Bellizzi added.

Currently, nearly 37 million people in the United States are 65 and older, and that number will probably double by 2030. Historically, older adults have been excluded from cancer clinical trials, so what is known about the effectiveness of screening in seniors is limited, he said.

The U.S. Preventive Services Task Force recommends against routine screening for breast, colorectal, and prostate cancer at age 75 and beyond, and advises against cervical cancer testing after 65, according to the study. Read more...

Ayurtox for Body Detoxification

Source:
http://feeds.feedburner.com/integratedmedicine

Tweet 

What follows is the record of "classifications" done by the ATMP CAT in 2011 related to anything I would call "cell therapies". 


In my opinion there are a couple surprises. I'm surprised at the non-cardiac cells (MNCs, CD133s, and MSCs) for cardiac disease/repair being designated TEPs. I'm also surprised at the islets not being classified as an ATMP.


I've tapped into my European and/or regulatory colleagues to help explain those two as well as help us draw any other conclusions or observations we can make in terms of how the CAT is thinking based on the compendium of classifications we have to-date.  I'll post an update here when I have something useful.
______


In January, the following product was classified as a tissue engineered product - not combined:

• Layer of autologous corneal epithelium containing stem cells intended for the treatment of extended corneal lesions

In April, the following product was classified as a tissue engineered product, combined: 

• Allogeneic human fibroblasts cultured onto a biodegradable matrix, intended for use of conditions in the therapeutic area of dermatology

In May, the following product was classified as a somatic cell therapy medicinal product: 

• Heterologous human adult liver-derived progenitor cells, intended for the treatment of inborn errors of liver metabolis

In July, the following product was classified as a Tissue Engineered Product, non-combined:

• Suspension of allogeneic bone-marrow derived osteoblastic cells, intended for the treatment of non-union, delayed union or other fractures. 

In September, the following product was classified as a Tissue Engineered Product, non-combined:

• Autologous mesenchymal stem cells (MSC), intended for the treatment of chronic heart failure symptoms by improvement in exercise capacity of NYHA class II and III chronic heart failure patients receiving standard therapy

     and the following product was not classified as an ATMP: 

• Human islets of Langerhans, intended for: Post pancreatectomy for benign pancreatic pathologies (autologous); Treatment of severe forms of type 1 diabetes (Allogeneic)

In October, the following product was classified as a somatic cell therapy medicinal product: 

• Autologous dendritic cell (DCs) immunotherapy consisting of autologous mature DCs coelectroporated with autologous RCC IVT RNA and synthetic CD40L IVT RNA, intended for the treatment of patients with advanced renal cell carcinoma

In November, the following products were classified as tissue-engineered products:

• Concentrate of autologous bone marrow mononuclear cells (MNC), intended for improvement of heart function and quality of life in patients with chronic ischaemic heart disease and after MI.
• CD 133+ Autologous bone marrow derived stem cells, intended for Improvement of heart function (LVEF) and quality of life in patients with chronic ischemic heart disease and after MI

In December, the following product was classified as somatic cell therapy medicinal product:

• Autologous CD4+ T cells targeted to cells presenting class II restricted epitopes, intended forthe treatment of autoimmune diseases with MHC restricted specific immunity e.g. multiple sclerosis, type I diabetes or graft rejection.

http://www.celltherapyblog.com hosted by http://www.celltherapygroup.com

Source:
http://feeds.feedburner.com/CellTherapyBlog

Inevitably, year-end lists invite plenty of debate and criticism, and Scientific American 's is no exception. Certainly, we could have included the discovery of new worlds beyond our solar system, including Kepler 22 b, an exoplanet in the "Goldilocks" zone of habitability, as well as the first known Earth-size exoplanets . Or noted the accumulating evidence suggesting that hydraulic fracturing, or fracking, to retrieve natural gas is likely to contaminate water supplies. (Final New York State regulations, expected in mid-2012, could determine the future of fracking in the U.S.)

[More]

Source:
http://rss.sciam.com/sciam/topic/gene-therapy

27-11-2011 23:17 Mouse with spinal cord injury before and after stem cells

See the original post:
MouseVideo-SCI - Video

Many of our patients travel to Guangzhou from all over the world for medical treatment and tourism. China medical tourism can help with becoming a patient, travel arrangements and language assistance

View original post here:
China medical tourism--spinal cord injury--stem cells therapy - Video

(HealthDay News) -- Men are less willing than women to be screened for cancer, even though men have higher cancer death rates, a new study shows.

Researchers conducted a telephone survey of nearly 1,150 adults in New York City, Baltimore, and San Juan, Puerto Rico, who answered questions from the Cancer Screening Questionnaire. Most of the participants were aged 30 to 59, and 35 percent of them were men.

"This study examined beliefs and attitudes held by men and women about cancer screening. Our aim was to gain insight for improving existing cancer health promotion practices," study corresponding author Jenna Davis, of the department of health outcomes and behavior at the Moffitt Cancer Center in Tampa, Fla., said in a center news release.

"Our findings indicate that there is a need for better health and cancer screening promotion among men," she said.

The researchers suggested several reasons why men are less willing than women to undergo cancer screening: most cancer awareness campaigns in the media are for women's breast cancer; there is a lack of government-sponsored men's cancer awareness campaigns; and studies indicate that women see their primary care doctor more often than men. Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

The $3 billion California stem cell agency should shut its doors when its cash runs out in about six years and turn over development of stem cell therapies to industry and academe, the San Jose Mercury News said in an editorial on Saturday.

The piece in the leading newspaper in California's Silicon Valley was headlined, "Stem Cell Institute Should Take a Bow (Out)."

The newspaper wrote,

"This state is in financial crisis with no full recovery in sight. Bankrolling the next phase of research would come at the expense of other critical state services, including public education, that are state government's core mission and already are starved by budget cuts. It would be a mistake to pile more debt onto the state's already heavy bond obligations, which are paid off from the same general fund that pays for schools and other services. Medical research is important, but it is not at the heart of state government's mission. Bond measures now need to deal with water supplies and other looming crises."

The editorial said CIRM has provided a "strong foundation from which universities and companies can move toward cures."

But the newspaper concluded,

"Cures remain elusive -- there is never a guarantee with scientific research -- but the 10-year start voters approved was meant to be just that. The promise of stem cell treatments now must be kept alive with funding from industry, academic institutions and private foundations and philanthropists."

The editorial comes as the seven-year-old agency is driving to turn research into therapies that can actually be used in treatments. At the same time, CIRM is considering asking California voters to approve another multibillion bond measure in the next few years, a proposal that seems to be fresh news to many in the media.

The San Jose newspaper covered the stem cell agency with some detail in its first year of operation. In the last few years, however, the paper's coverage has been all but non-existent, like most of the news media in California.

Earlier this month, the paper published an overview of the agency, which highlighted the discussions by former CIRM Chairman Bob Klein about another bond issue, along with the fact that the cures promised by the campaign of 2004 have not materialized. The proposed bond issue is old news for most persons who have followed CIRM; the plan has been around publicly for more than a year. But the call for more cash comes a surprise to many of in the media. And to the public. So it is likely to pop up again as other news outlets re-visit the agency from time to time.

The presence of another electoral campaign also imposes a different sort of burden on CIRM – something quite removed from such matters as the basic biology of stem cells. It means that the stem cell agency's endeavors are being evaluated in a political context, which involves such questions as whether its actions are designed to generate the millions in campaign contributions necessary to win a statewide election or whether it is neglecting valuable research for something that will instead generate a high profile result for the benefit of the campaign but not add much to the science.

It is all part of tactics and strategy involved in the "communications war" that CIRM Chairman Jonathan Thomas discussed with CIRM board members last June in his bid to win election to his post.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

Advanced Cell Technology, which has unsuccessfully sought funding several times from the $3 billion California stem cell agency, drew some attention today in a piece in a Massachusetts newspaper.

The Worcester Telegram took a look at the firm, headquartered in Santa Monica, Ca., with labs in Marlboro, Mass., in the wake of Geron's departure from hESC research. The move left ACT as the only firm in the country with an hESC trial and perhaps with a better shot at CIRM funding.

Reporter Lisa Eckelbecker wrote,

"Advanced Cell, publicly traded since 2005, has spent years developing its technologies. The company brings in little revenue and has an accumulated deficit of $180.9 million. About 1.6 billion shares of Advanced Cell common stock is outstanding, a result of numerous financings over the years. It trades for about 10 cents a share on the Over-the-Counter Bulletin Board, an electronic exchange for small companies. No analysts from major Wall Street banks report on the company.

"The company's treatment for Stargardt's macular dystrophy and dry age-related macular degeneration — the treatment that required (a) mountain of paperwork before the FDA — first went into the eyes of patients in July in Los Angeles. The retinal pigment epithelial cells, generated from embryonic stem cells, were developed to slow the progression of the eye disorders, which can lead to blindness."

ACT moved its headquarters to California following the passage of Prop. 71 in 2004, the ballot initiative that created the California stem cell agency. The company said at the time it expected to "gain significant momentum by being able to take advantage of a favorable environment for funding."

ACT initially landed in Alameda, Ca., but has since moved to Southern California. Its official opening in 2006 in Alameda was attended by the state treasurer and at least one CIRM official, according to the company. The firm has never secured funding from the stem cell agency, which does not release the names of rejected applicants. However, the California Stem Cell Report carried an item in 2008 that pointed out that a researcher for ACT complained publicly about a reviewer's conflict of interest in connection with an ACT application(see here and here). At the time, Robert Klein, then CIRM chairman, brushed off the complaint. The journal Nature has also reported that ACT has applied unsuccessfully several times for CIRM awards.

It is a fair bet that ACT was an initial applicant in the round that provided funding to Geron last spring. However, by the time Geron's application went to the full CIRM board, the other applicants had withdrawn – the first time such an event had occurred at CIRM.

Since Geron pulled out of the hESC business last month, it is likely that ACT and CIRM have opened fresh discussions, given their mutual interest in producing a stem cell therapy. CIRM also has a new chairman who is familiar with ACT. After Geron was awarded its $25 million loan from CIRM last May, the agency's board elected as chairman a Los Angeles bond financier, Jonathan Thomas, who led an early round of financing for ACT in 2000. Thomas last summer sold his remaining 17,046 shares in ACT for $3,239. Thomas said he had a "significant loss" on the sale but did not disclose the amount.

Geron's flight from hESC and ACT's perserverance come as the stem cell agency is pushing aggressively to drive research into the clinic. Plus CIRM needs tangible results that voters can understand if CIRM is win ballot-box approval for continued funding in the next few years. The agency will run out of cash in about 2017 and is considering mounting a campaign for another multibillion bond issue.

Source:
http://californiastemcellreport.blogspot.com/feeds/posts/default?alt=rss

I recently had the life changing experience of becoming a bone marrow donor (more specifically, a peripheral blood stem cell (PBSC) donor. As I learned more about how many people need a transplant and how surprisingly easy the process was, I knew this was an issue I would become passionate about.

View post:
My Personal Experience in Donating Bone Marrow/Stem cells. Be a Donor, Fight Leukemia- Bradford Pine - Video

Wawa, QC Chemist of Imed Lab Sdn Bhd explains and demo about Glamore Halal Stem Cell Vitalization, built with EverLaSkin as active ingredients, to stimulate dormant stem cells under your skin -- stem cells that are able to regenerate and repair skin tissue, and counterbalance the aging epidermal cells with new and young cells. Imed Lab Sdn Bhd is a manufacturer of halal cosmetic products.

More here:
GlamoreTV: Glamore Stem Cell Vitalization - Video

Charles H. Tator, CM, MD, MA, PhD, FRCSC, FACS Hear Dr

Read more from the original source:
Which Stem Cell Will Win The Race To Repair The Spinal Cord? - Video

http://www.jeteye.com The splendor

Visit link:
Stem Cell Therapy Anti Aging Skin Cream Review and Exclusive Deal - Video

GeneCell International is one of the leaders in the field of stem cell banking. We operate a laboratory that focuses on processing and cryopreserving of stem cells derived from umbilical cord blood, dental pulp, adipose tissue, other tissues, and cells that can be cryogenically preserved.

Read more:
GeneCell International on Miami Moms - Video

CIRM has funded a $5.5 million Disease Team to develop a follow on clinical trial that uses a patient's own heart stem cells to regenerate scarred tissue damaged by a heart attack. The team is led by Eduardo Marban, MD, PhD, Director of the Cedars-Sinai Heart Institute. Marban presented the team's latest progress at the December 8th, 2011 CIRM Governing Board meeting

See more here:
Stem Cell Clinical Trial for Heart Failure: Eduardo Marban - CIRM Spotlight on Disease - Video

Israeli researchers have managed for the first time to repair damaged tissue using components produced by embryonic stem cells.

Continued here:
Israeli researchers use stem cells to repair damaged tissue for first time - Video

What do Parkinsons disease and anti-aging skin care have in common? A lot actually Dr. Manny talks to one researcher who stumbled up a fountain of youth secret while trying to find a cure for a devastating disease

Read the original here:
Stem Cells for Your Skin? - Video

As with umbilical cord blood banking, GeneCell International is at the forefront of the research and the technology developed to process and store stem cells found within the dental pulp. Although most people are familiar with banking cord , few people are aware of the advantages of harvesting stem cells from the dental pulp: •Dental pulp can be obtained unobtrusively as children or adults lose teeth •The stem cells found in dental pulp are non-controversial adult stem cells (mesenchymal stem cells) •Dental pulp stem cells are excellent candidates for regenerative medicine and tissue engineering applications GeneCell International is committed to excellence in cell processing and cryogenically storing your dental pulp stem cells.

Read the original here:
GeneCell International Dental Pulp Stem Cell's Banking Services - Video

(HealthDay News) -- Radiologists have developed a way to gain better insight into signs of heart disease by using cardiac CT scans that detect narrowed arteries and low blood flow.

CT scans use X-rays to create cross-sectional images of the body's internal anatomy. The scans can detect blockages in coronary arteries, but it's hard to tell if they're actually preventing blood from flowing to the heart.

In a new study, published Sept. 15 in the Journal of the American College of Cardiology, researchers at Massachusetts General Hospital explained how to gain more detailed pictures of what is going on inside the body, potentially giving doctors more information about the best treatment.

The research, based on tests in 34 cardiac patients, "is among the first demonstrations of the use of cardiac CT to detect both coronary artery stenosis and resulting myocardial ischemia simultaneously in a single examination," Dr. Ricardo C. Cury, a cardiac imaging specialist at the hospital's Heart Center and the study's principal investigator, explained in a hospital news release. Read more...

Cardiofy Heart Care Supplement

Source:
http://feeds.feedburner.com/integratedmedicine

Modern-day biotechnology is restorative healing the entire world by means of taking nature’s individual resource as well as neurological operations. Throughout curing the world, biotechnology is decreasing the rates connected with contagious disease, overcoming life-threatening problems, generating customized treatments possible, in addition to preserving the particular lifestyles of these suffering with exceptional illnesses.
Particularly, medical provides the probable involving handling unmet healthcare desires for individuals along with cancers and HIV/AIDS while at the same time period assists in the therapy or even protection against strokes, heart stroke, liver disease and leukemia, amid all kinds of other critical diseases. 

Spotting the position of recent medical, this Department of Surroundings and also Natural Means (DENR) organised this special event with the “7th National Biotechnology Week” from November. 21 years old for you to Twenty six. This occasion coincided together with the Food items and also Substance Administration-led “National Consciousness Week Against Phony Medicines” using the assistance on the pharmaceutic market, along with medical in addition to para-medical specialized businesses.

This week-long celebration seemed to be supported by some other government departments involved in biotechnology study. Some other collaborating gov departments were this sections regarding Science and Technology, Health, and also Agriculture.

Source:
http://www.biotechblog.org/rss.xml